Format
Items per page
Sort by

Send to:

Choose Destination

Links from

Items: 14

1.
Full record GDS5266

Cyclin-dependent kinase inhibitor R547 effect on peripheral blood mononuclear cells: dose response and time course

Analysis of peripheral blood mononuclear cells treated with CDK inhibitor R547 at 2 doses for 2 and 24 hours. R547 exerts an antiproliferative effect on various cell lines. Results compared with those from DU145 (GDS5267) and HCT116 cells (GDS5268) to identify pharmacodynamic biomarkers for R547.
Organism:
Homo sapiens
Type:
Expression profiling by array, count, 3 agent, 3 dose, 3 time sets
Platform:
GPL570
Series:
GSE15389
37 Samples
Download data: CEL
DataSet
Accession:
GDS5266
ID:
5266
2.

Peripheral blood mononuclear, DU145, and HCT116 cells treated with a CDK inhibitor

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
156 Samples
Download data: CEL
Series
Accession:
GSE15396
ID:
200015396
3.

HCT116 tumor cells treated with a CDK inhibitor

(Submitter supplied) A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS5268
Platform:
GPL570
74 Samples
Download data: CEL
Series
Accession:
GSE15395
ID:
200015395
4.

DU145 tumor cells treated with a CDK inhibitor

(Submitter supplied) A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS5267
Platform:
GPL570
45 Samples
Download data: CEL
Series
Accession:
GSE15392
ID:
200015392
5.

Peripheral blood mononuclear cells treated with a CDK inhibitor

(Submitter supplied) A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS5266
Platform:
GPL570
37 Samples
Download data: CEL
Series
Accession:
GSE15389
ID:
200015389
6.
Full record GDS5268

Cyclin-dependent kinase inhibitor R547 effect on colon cancer cell line: dose response and time course

Analysis of HCT116 colon cancer cells treated with the CDK inhibitor R547 at 3 doses for up to 24 hours. R547 exerts an antiproliferative effect on various cell lines. Results compared with those from PBMCs (GDS5266) and DU145 cells (GDS5267) to identify pharmacodynamic biomarkers for R547.
Organism:
Homo sapiens
Type:
Expression profiling by array, count, 3 agent, 4 dose, 6 time sets
Platform:
GPL570
Series:
GSE15395
74 Samples
Download data: CEL
DataSet
Accession:
GDS5268
ID:
5268
7.
Full record GDS5267

Cyclin-dependent kinase inhibitor R547 effect on prostate cancer cell line: dose response and time course

Analysis of DU145 prostate cancer cells treated with the CDK inhibitor R547 at 3 doses for up to 24 hours. R547 exerts an antiproliferative effect on various cell lines. Results compared with those from PBMCs (GDS5266) and HCT116 cells (GDS5268) to identify pharmacodynamic biomarkers for R547.
Organism:
Homo sapiens
Type:
Expression profiling by array, count, 3 agent, 4 dose, 4 time sets
Platform:
GPL570
Series:
GSE15392
45 Samples
Download data: CEL
DataSet
Accession:
GDS5267
ID:
5267
8.

Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study

(Submitter supplied) Microarray analysis of transcriptional changes in biopsies of solid tumors from patients treated in a Phase I study with the Cdk inhibitor PHA-793887.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL6480
7 Samples
Download data: TXT
Series
Accession:
GSE18553
ID:
200018553
9.

Identification of potential ABBV-075 responsive markers in mouse whole blood

(Submitter supplied) To identify genes that are modulated by BET inhibitors in blood, we determined global gene expression changes in ABBV-075-treated mouse whole blood samples
Organism:
Mus musculus
Type:
Expression profiling by array
Platform:
GPL1261
15 Samples
Download data: CEL
Series
Accession:
GSE89935
ID:
200089935
10.

Identification of potential ABBV-075 responsive markers in mouse skin

(Submitter supplied) Determination of transcriptional alterations in skin samples from ABBV-075 treated mice
Organism:
Mus musculus
Type:
Expression profiling by array
Platform:
GPL1261
11 Samples
Download data: CEL
Series
Accession:
GSE89934
ID:
200089934
11.

Identification of potential ABBV-075 responsive markers in human PBMCs

(Submitter supplied) To identify genes that are modulated by BET inhibitors in blood, we determined global gene expression changes in ABBV-075-treated human PBMC samples
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL571
10 Samples
Download data: CEL
Series
Accession:
GSE89933
ID:
200089933
12.

Identification of genes that are modulated by BET inhibitors in cancer cells to identify robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissue

(Submitter supplied) Competitive inhibitors of acetyl-lysine binding to the bromodomains of the BET (bromodomain and extra terminal) family are being developed for the treatment of solid and heme malignancies. BET family member BRD4 function at enhancers/super-enhancers has been shown to sustain signal-dependent or pathogenic gene expression programs.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL571
36 Samples
Download data: CEL
Series
Accession:
GSE89932
ID:
200089932
13.

Contribution of BET proteins to androgen (DHT)-stimulated gene expression program

(Submitter supplied) Competitive inhibitors of acetyl-lysine binding to the bromodomains of the BET (bromodomain and extra terminal) family are being developed for the treatment of solid and heme malignancies. BET family member BRD4 function at enhancers/super-enhancers has been shown to sustain signal-dependent or pathogenic gene expression programs. Here we tested the hypothesis that the transcription factor drivers of castration-resistant prostate cancer (CRPC) clinical progression, including the Androgen Receptor (AR), are critically dependent on BRD4 and thus represent a sensitive solid tumor indication for the BET inhibitor ABBV-075. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
8 Samples
Download data: CEL
Series
Accession:
GSE86245
ID:
200086245
14.

THZ1-induced transcriptional changes in SMO inhibitor responsive and resistant mouse hedgehog-driven medulloblastoma cells

(Submitter supplied) Purpose: To assess THZ1-induced global changes of transcriptome of Hh-driven cancer Methods: SMB56 or SMB56-shSufu cells were mouse hedgehog-driven medulloblastoma cell lines that are either responsive or resistant to SMO inhibitor (GDC-0449). They were treated with 0.1 uM THZ1 or DMSO for 8 hours. 1 uM GDC-0449 treated SMB56 cells were included as control. Gene expression profiles were generated by RNAseq, in duplicate, using Hiseq3000. more...
Organism:
Mus musculus
Type:
Expression profiling by high throughput sequencing
Platforms:
GPL21493 GPL21273
10 Samples
Download data: XLSX
Series
Accession:
GSE130485
ID:
200130485
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=1|qty=3|blobid=MCID_61a41c9a086ba1408a5dacde|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center